Stock Research for DRRX

DRRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

DRRX Stock Chart & Research Data

The DRRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DRRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


DRRX Due diligence Resources & Stock Charts

The DRRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DRRX Detailed Price Forecast - CNN Money CNN View DRRX Detailed Summary - Google Finance
Yahoo View DRRX Detailed Summary - Yahoo! Finance Zacks View DRRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View DRRX Trends & Analysis - Trade-Ideas Barrons View DRRX Major Holders - Barrons
NASDAQ View DRRX Call Transcripts - NASDAQ Seeking View DRRX Breaking News & Analysis - Seeking Alpha
Spotlight View DRRX Annual Report - CompanySpotlight.com OTC Report View DRRX OTC Short Report - OTCShortReport.com
TradeKing View DRRX Fundamentals - TradeKing Charts View DRRX SEC Filings - Bar Chart
WSJ View Historical Prices for DRRX - The WSJ Morningstar View Performance/Total Return for DRRX - Morningstar
MarketWatch View the Analyst Estimates for DRRX - MarketWatch CNBC View the Earnings History for DRRX - CNBC
StockMarketWatch View the DRRX Earnings - StockMarketWatch MacroAxis View DRRX Buy or Sell Recommendations - MacroAxis
Bullish View the DRRX Bullish Patterns - American Bulls Short Pains View DRRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View DRRX Stock Mentions - StockTwits PennyStocks View DRRX Stock Mentions - PennyStockTweets
Twitter View DRRX Stock Mentions - Twitter Invest Hub View DRRX Investment Forum News - Investor Hub
Yahoo View DRRX Stock Mentions - Yahoo! Message Board Seeking Alpha View DRRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for DRRX - SECform4.com Insider Cow View Insider Transactions for DRRX - Insider Cow
CNBC View DRRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DRRX - OTC Markets
Yahoo View Insider Transactions for DRRX - Yahoo! Finance NASDAQ View Institutional Holdings for DRRX - NASDAQ


Stock Charts

FinViz View DRRX Stock Insight & Charts - FinViz.com StockCharts View DRRX Investment Charts - StockCharts.com
BarChart View DRRX Stock Overview & Charts - BarChart Trading View View DRRX User Generated Charts - Trading View




Latest Financial News for DRRX


Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Posted on Thursday December 13, 2018

Q3 2018 DURECT Corp Earnings Call


Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Friday November 30, 2018

NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.


DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
Posted on Monday November 19, 2018

CUPERTINO, Calif. , Nov. 19, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients ...


DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream
Posted on Friday November 16, 2018

DRRX is also eligible for single-digit percentage earn-outs based on U.S. sales of PERSERIS.  Indivior indicated that they expect to have initial quantities available in Q4 ’18 and, based on the outcome of an appeal by Dr. Reddy’s lab (DRL) challenging the U.S. District Court of New Jersey’s preliminary injunction (PI) prohibiting DRL from importing or selling its generic buprenorphine/naloxone sublingual film product, expect to commence a full product launch.  A favorable outcome (i.e.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.